Discover and read the best of Twitter Threads about #solidarityTrial
Most recents (4)
Daily Bookmarks to GAVNet 08/11/2021 greeneracresvaluenetwork.wordpress.com/2021/08/11/dai…
A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19
frontiersin.org/articles/10.33…
#GlucoseLevels #COVID19 #MachineLearning #models #analysis
frontiersin.org/articles/10.33…
#GlucoseLevels #COVID19 #MachineLearning #models #analysis
Internet Archive’s Modern Book Collection Now Tops 2 Million Volumes
blog.archive.org/2021/02/03/int…
#InternetArchive #BookCollection #volumes
blog.archive.org/2021/02/03/int…
#InternetArchive #BookCollection #volumes
With the .@NIAIDNews #ACCT1 trial final report published on 05 Nov 2020 and the .@WHO's #SolidarityTrial Preliminary report published on 02 December 2020, thought it would be good to take another look at both trials and find ways forward for the patients we are dealing with today 
Motivated by a patient I am dealing with who will survive very severe #COVID19 in the setting of transplant, but her father, who was hospitalized earlier than her with moderate COVID, was left to progress and died before her discharge, given #remdesivir only after going on #BiPAP
Here is the link to the prior analysis and I think the new publications give some interesting details which will follow
Time to share some thoughts and questions following the .@medrxivpreprint first release of results from the #SolidarityTrial that compared local standard care to #remdesivir, #HydroxyChloroquine #lopinavir_ritonavir and #interferon for treatment of patients with #COVID19
I have read the #solidarityTrial preprint: medrxiv.org/content/10.110…
Its supplementary material:medrxiv.org/content/10.110…
its posted protocol: who.int/publications/m…
The CRF: who.int/publications/i…
The final report from #ACTT1 for contrast: nejm.org/doi/full/10.10…
Its supplementary material:medrxiv.org/content/10.110…
its posted protocol: who.int/publications/m…
The CRF: who.int/publications/i…
The final report from #ACTT1 for contrast: nejm.org/doi/full/10.10…
Everyone has focused on the results, which is understandable, yet understanding the specifics in #SolidarityTrial design compared to the #ACTT1 design, may bring light into the differences reported between trials and may give a way to do better in #COVID19 #therapeutics
Correspondence justifying ICMR's guideline for using #HCQ for prophylaxis in healthcare workers, in @TheLancet by AIIMS medicine department. My first thought: "They're the experts, so there must be some good science behind it!" To convince myself, I dig a little deeper
1/n
1/n
Ref 4: open-label, non-randomized trial. 26 received HCQ (but 6 lost to follow up), 16 controls. Adjusted for age and sex. NO DATA ON CO-MORBIDITIES. Result-HCQ led to significant reduction of viral carriage ar D6. Azithromycin if added more efficient. sciencedirect.com/science/articl…
2/n
2/n
Counter-evidence: study published in @TheLancet two days back. 671 hospital, 6 continents. 81k control group. 3k received HCQ, 6k HCQ + Azithro. Controlled for comorbidities. HCQ and HCQ + Azithro independently associated w/ inc risk of mortality and ventricular arrhythmia.
3/n
3/n
